Form 8-K · Current report
McKesson Corporation 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0000927653
- Accession no.
- 0000927653-26-000279
Summary
McKesson reported fiscal 2027 second-quarter revenues of $111.0 billion, up 8%, and adjusted earnings per diluted share of $11.68, up 18%, and raised its full-year adjusted EPS guidance to $45.60–$46.40 from $44.20–$45.00. The company also signed an agreement extending its pharmaceutical distribution partnership with CVS Health through June 2032, agreed to invest about $1.4 billion for a roughly 49% minority stake in Option Care Health, and completed the acquisition of Precision Medicine Group.
Key points
- Second-quarter revenues were $111.0 billion, up 8% from a year earlier, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments.
- The company generated $3.1 billion of cash from operations and $2.9 billion of free cash flow in the quarter, and returned $3.6 billion to shareholders over the first six months.
- The approximately $1.4 billion investment for a roughly 49% minority interest in Option Care Health is subject to Option Care Health stockholder approval and regulatory approvals.
- PRISM Vision Group added Spectrum Vision Partners, more than 150 providers, bringing its network to over 350 providers.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on September 30, 2026 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.